Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
The U.S. Food and Drug Administration (FDA) has granted fast track designation with rolling review to Lumicell’s LUM Imaging System for the detection and treatment of breast cancer. Fast track ... Read more
Trodelvy (sacituzumab govitecan), compared with standard chemotherapy, significantly prolonged overall survival and improved the overall response rate of patients with metastatic triple-negative breast cancer (mTNBC) who had at least two prior ... Read more
When given alongside endocrine therapy (ET), Verzenio (abemaciclib) can lower the risk of cancer recurrence and spread compared to standard ET alone in patients with certain forms of early breast cancer ... Read more
The Australian Therapeutic Goods Administration (TGA) has approved Seattle Genetics’ Tukysa (tucatinib), when given alongside trastuzumab and Xeloda (capecitabine), for the treatment of patients with advanced inoperable or metastatic HER2-positive breast cancer, who received ... Read more
The U.S. Food and Drug Administration (FDA) has accepted to review two new Merck applications requesting the approval of Keytruda (pembrolizumab) for the treatment of patients with different forms of ... Read more
Devyser’s hereditary breast and ovarian cancer (HBOC) test has received a CE mark from the European Commission and is now approved as a diagnostic test for both cancers in Europe. The CE mark is ... Read more
Immunomedics has announced that its Phase 3 ASCENT trial of Trodelvy (sacituzumab govitecan) met its main goal of demonstrating that the medication is superior to standard chemotherapy at delaying disease ... Read more
When given alongside chemotherapy, Tecentriq (atezolizumab) increases the percentage of people with early triple-negative breast cancer (TNBC) who show no signs of cancer during tumor removal surgery, a Phase 3 trial ... Read more
An independent data monitoring committee (DMC) has deemed it unlikely that a combination of endocrine therapy and Pfizer’s Ibrance (palbociclib) will show benefits over standard therapy at delaying or preventing ... Read more
Scientists have discovered a gene signature in certain types of breast cancer that can be used to determine the likelihood of these tumors responding to treatment with a new class ... Read more
// Fill in your MailChimp popup settings below.
// These can be found in the original popup script from MailChimp.
var mailchimpConfig = {
baseUrl: 'mc.us5.list-manage.com',
uuid: '52c64784d386bd00ea57ee792',
lid: 'ea3614260e'
};
// No edits below this line are required
var chimpPopupLoader = document.createElement("script");
chimpPopupLoader.src = '//s3.amazonaws.com/downloads.mailchimp.com/js/signup-forms/popup/embed.js';
chimpPopupLoader.setAttribute('data-dojo-config', 'usePlainJson: true, isDebug: false');
var chimpPopup = document.createElement("script");
chimpPopup.appendChild(document.createTextNode('require(["mojo/signup-forms/Loader"], function (L) { L.start({"baseUrl": "' + mailchimpConfig.baseUrl + '", "uuid": "' + mailchimpConfig.uuid + '", "lid": "' + mailchimpConfig.lid + '"})});'));
jQuery(function ($) {
//document.body.appendChild(chimpPopupLoader);
//$(window).load(function () {
// document.body.appendChild(chimpPopup);
});
});
